BioMorph Inc.

Biomorph is developing nanoparticle-based drug carriers that enable precise drug delivery, particularly targeting neurological disorders where conventional drugs struggle to cross the blood-brain barrier. Our carriers improve drug bioavailability, reduce dosage requirements, and minimize side effects, making treatments more effective and patient-friendly. Our unique selling proposition lies in our biodegradable and highly adaptable nanocarriers, which can be customized to various drugs, offering versatility across multiple therapeutic areas such as neurology, oncology, and rare diseases. Unlike conventional formulations, our carriers ensure higher precision with lower systemic toxicity. We are initially targeting pharmaceutical companies seeking innovative drug delivery platforms and research institutions for preclinical studies, focusing on India, the US, and Europe. Our entry barriers include proprietary formulation techniques, collaborations with leading research labs, and a strong regulatory framework to ensure compliance with global biotech standards.